AMLX
Amylyx Pharmaceuticals Inc

2,189
Mkt Cap
$1.57B
Volume
267,588.00
52W High
$16.96
52W Low
$2.60
PE Ratio
-7.96
AMLX Fundamentals
Price
$14.49
Prev Close
$14.32
Open
$14.45
50D MA
$13.63
Beta
1.72
Avg. Volume
1.73M
EPS (Annual)
-$4.43
P/B
4.73
Rev/Employee
$710,333.33
Loading...
Loading...
News
all
press releases
Los Angeles Capital Management LLC Takes $149,000 Position in Amylyx Pharmaceuticals, Inc. $AMLX
Los Angeles Capital Management LLC bought a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Up 6.5% - Here's Why
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Up 6.5% - Still a Buy...
MarketBeat·2d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Sells 45,206 Shares of Amylyx Pharmaceuticals, Inc. $AMLX
Connor Clark & Lunn Investment Management Ltd. lessened its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 3.8% during the second quarter, according to its most recent...
MarketBeat·6d ago
News Placeholder
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. AMLX
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX...
Business Wire·9d ago
News Placeholder
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Moderate Buy" from Brokerages
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the stock, MarketBeat...
MarketBeat·9d ago
News Placeholder
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?
Here is how Exact Sciences (EXAS) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
Zacks·10d ago
News Placeholder
Q1 Earnings Estimate for AMLX Issued By HC Wainwright
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a research note...
MarketBeat·10d ago
News Placeholder
Amylyx Pharmaceuticals (NASDAQ:AMLX) Posts Earnings Results, Beats Estimates By $0.06 EPS
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·12d ago
News Placeholder
Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $20.00 at HC Wainwright
HC Wainwright increased their price objective on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Friday...
MarketBeat·12d ago
News Placeholder
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx senior management team will host a...
Business Wire·21d ago

Latest AMLX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.